Nonclinical safety strategies for stem cell therapies

被引:44
作者
Sharpe, Michaela E. [1 ]
Morton, Daniel [2 ]
Rossi, Annamaria [1 ]
机构
[1] Pfizer Ltd, Drug Safety Res & Dev, Investigat Toxicol, Sandwich CT13 9NJ, Kent, England
[2] Pfizer Inc, Drug Safety Res & Dev, Exploratory Drug Safety, Cambridge, MA 02140 USA
关键词
Stem cells; Biodistribution; Immunogenicity; Tumorigenicity; Toxicology; Safety studies; HUMAN BONE-MARROW; PROGENITOR CELLS; IMMUNOLOGICAL-PROPERTIES; TERATOMA FORMATION; CLINICAL-TRIALS; STROMAL CELLS; TRANSPLANTATION; ENGRAFTMENT; EXPRESSION; DIFFERENTIATION;
D O I
10.1016/j.taap.2012.05.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent breakthroughs in stem cell biology, especially the development of the induced pluripotent stem cell techniques, have generated tremendous enthusiasm and efforts to explore the therapeutic potential of stem cells in regenerative medicine. Stem cell therapies are being considered for the treatment of degenerative diseases, inflammatory conditions, cancer and repair of damaged tissue. The safety of a stem cell therapy depends on many factors including the type of cell therapy, the differentiation status and proliferation capacity of the cells, the route of administration, the intended clinical location, long term survival of the product and/or engraftment, the need for repeated administration, the disease to be treated and the age of the population. Understanding the product profile of the intended therapy is crucial to the development of the non-clinical safety study design. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:223 / 231
页数:9
相关论文
共 79 条
  • [1] ACT, 2011, WORLD STEM CELLS REG
  • [2] Second malignancies after allogeneic hematopoietic stem cell transplantation:: new insight and current problems
    Adès, L
    Guardiola, P
    Socié, G
    [J]. BLOOD REVIEWS, 2002, 16 (02) : 135 - 146
  • [3] Human mesenchymal stem cells modulate allogeneic immune cell responses
    Aggarwal, S
    Pittenger, MF
    [J]. BLOOD, 2005, 105 (04) : 1815 - 1822
  • [4] Mesenchymal stem cell therapy: Two steps forward, one step back
    Ankrum, James
    Karp, Jeffrey M.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2010, 16 (05) : 203 - 209
  • [5] Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response
    Badillo, Andrea T.
    Beggs, Kirstin J.
    Javazon, Elisabeth H.
    Tebbets, Jessica C.
    Flake, Alan W.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (04) : 412 - 422
  • [6] Adaptation to culture of human embryonic stem cells and oncogenesis in vivo
    Baker, Duncan E. C.
    Harrison, Neil J.
    Maltby, Edna
    Smith, Kath
    Moore, Harry D.
    Shaw, Pamela J.
    Heath, Paul R.
    Holden, Hazel
    Andrews, Peter W.
    [J]. NATURE BIOTECHNOLOGY, 2007, 25 (02) : 207 - 215
  • [7] Immunogenicity of adult mesenchymal stem cells: Lessons from the fetal allograft
    Barry, FP
    Murphy, JM
    English, K
    Mahon, BP
    [J]. STEM CELLS AND DEVELOPMENT, 2005, 14 (03) : 252 - 265
  • [8] A HUMAN-SPECIFIC SUBFAMILY OF ALU-SEQUENCES
    BATZER, MA
    DEININGER, PL
    [J]. GENOMICS, 1991, 9 (03) : 481 - 487
  • [9] The tumorigenicity of diploid and aneuploid human pluripotent stem cells
    Blum, Barak
    Benvenisty, Nissim
    [J]. CELL CYCLE, 2009, 8 (23) : 3822 - 3830
  • [10] Molecular Trafficking Mechanisms of Multipotent Mesenchymal Stem Cells Derived from Human Bone Marrow and Placenta
    Brooke, Gary
    Tong, Hui
    Levesque, Jean-Pierre
    Atkinson, Kerry
    [J]. STEM CELLS AND DEVELOPMENT, 2008, 17 (05) : 929 - 940